TW200840869A - Papillomavirus vaccine - Google Patents
Papillomavirus vaccine Download PDFInfo
- Publication number
- TW200840869A TW200840869A TW097103230A TW97103230A TW200840869A TW 200840869 A TW200840869 A TW 200840869A TW 097103230 A TW097103230 A TW 097103230A TW 97103230 A TW97103230 A TW 97103230A TW 200840869 A TW200840869 A TW 200840869A
- Authority
- TW
- Taiwan
- Prior art keywords
- hpv
- nucleic acid
- acid molecule
- polypeptide
- polypeptides
- Prior art date
Links
- 229960002566 papillomavirus vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 313
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 290
- 229920001184 polypeptide Polymers 0.000 claims abstract description 282
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 211
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 211
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 211
- 239000013598 vector Substances 0.000 claims abstract description 123
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 113
- 208000015181 infectious disease Diseases 0.000 claims abstract description 77
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 239000002245 particle Substances 0.000 claims abstract description 63
- 239000002773 nucleotide Substances 0.000 claims abstract description 54
- 230000002458 infectious effect Effects 0.000 claims abstract description 53
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 53
- 230000003612 virological effect Effects 0.000 claims abstract description 47
- 208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 24
- 230000002085 persistent effect Effects 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 135
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 241000700605 Viruses Species 0.000 claims description 60
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 claims description 49
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 42
- 239000012528 membrane Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 230000010076 replication Effects 0.000 claims description 24
- 230000004048 modification Effects 0.000 claims description 23
- 238000012986 modification Methods 0.000 claims description 23
- 238000011282 treatment Methods 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- 230000002950 deficient Effects 0.000 claims description 20
- 101000622327 Human papillomavirus type 18 Regulatory protein E2 Proteins 0.000 claims description 18
- 101000954454 Human papillomavirus type 16 Replication protein E1 Proteins 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 231100001223 noncarcinogenic Toxicity 0.000 claims description 14
- 239000013603 viral vector Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000003154 papilloma Diseases 0.000 claims description 12
- 101000775744 Human papillomavirus type 18 Replication protein E1 Proteins 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 9
- 102000003886 Glycoproteins Human genes 0.000 claims description 9
- 108700038832 HPV-33 E2 Proteins 0.000 claims description 9
- 241000700618 Vaccinia virus Species 0.000 claims description 9
- 230000005860 defense response to virus Effects 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 8
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000003248 secreting effect Effects 0.000 claims description 7
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 238000004873 anchoring Methods 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 5
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 5
- 230000029812 viral genome replication Effects 0.000 claims description 5
- 206010037742 Rabies Diseases 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 3
- 208000037581 Persistent Infection Diseases 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 241000709727 Human poliovirus 3 Species 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 208000029211 papillomatosis Diseases 0.000 claims 2
- 108010076278 Adenosine kinase Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 79
- 241000701806 Human papillomavirus Species 0.000 description 36
- 230000003902 lesion Effects 0.000 description 34
- 238000000034 method Methods 0.000 description 30
- 230000004927 fusion Effects 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 210000002706 plastid Anatomy 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000035772 mutation Effects 0.000 description 17
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 16
- 238000001415 gene therapy Methods 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 238000011160 research Methods 0.000 description 15
- 108020004705 Codon Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 206010008263 Cervical dysplasia Diseases 0.000 description 11
- 239000013543 active substance Substances 0.000 description 11
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 11
- 239000002054 inoculum Substances 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 9
- 230000003211 malignant effect Effects 0.000 description 9
- 208000024794 sputum Diseases 0.000 description 9
- 210000003802 sputum Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 101150082674 E2 gene Proteins 0.000 description 7
- -1 Plastids Substances 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 101710125507 Integrase/recombinase Proteins 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108700020796 Oncogene Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 108700005077 Viral Genes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 101150029662 E1 gene Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101150106931 IFNG gene Proteins 0.000 description 4
- 102220543674 Protein patched homolog 2_E39A_mutation Human genes 0.000 description 4
- 241000711798 Rabies lyssavirus Species 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000010307 cell transformation Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 3
- 241000701822 Bovine papillomavirus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000701828 Human papillomavirus type 11 Species 0.000 description 3
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000009088 enzymatic function Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 101100102460 Human papillomavirus type 16 E2 gene Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010046905 Vaginal dysplasia Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000002621 cervical conization Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 229940101578 microlipid Drugs 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000006490 viral transcription Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 101150029062 15 gene Proteins 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 101100272719 Arabidopsis thaliana BRG3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102220595904 Endonuclease_E43A_mutation Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 101100540286 Human papillomavirus type 16 E1 gene Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical group OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100348738 Mus musculus Noc3l gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical group CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000004062 Tumor Virus Infections Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 229910001570 bauxite Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 208000016420 cervical intraepithelial neoplasia grade 2/3 Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- MKZGVLPHKXXSSG-UHFFFAOYSA-N ethyl n-[4-[benzyl(2-phenylethyl)amino]-2-[4-(trifluoromethyl)phenyl]-1h-imidazo[4,5-c]pyridin-6-yl]carbamate Chemical compound N=1C(NC(=O)OCC)=CC=2NC(C=3C=CC(=CC=3)C(F)(F)F)=NC=2C=1N(CC=1C=CC=CC=1)CCC1=CC=CC=C1 MKZGVLPHKXXSSG-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940124866 human papillomavirus vaccine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000018024 regulation of viral transcription Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220285342 rs777971423 Human genes 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360004 | 2007-01-30 | ||
| EP07360018 | 2007-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200840869A true TW200840869A (en) | 2008-10-16 |
Family
ID=39399907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097103230A TW200840869A (en) | 2007-01-30 | 2008-01-29 | Papillomavirus vaccine |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8420103B2 (enExample) |
| EP (2) | EP2390340A3 (enExample) |
| JP (1) | JP5474567B2 (enExample) |
| KR (1) | KR101636575B1 (enExample) |
| CN (1) | CN101617052A (enExample) |
| AR (1) | AR065076A1 (enExample) |
| AT (1) | ATE518958T1 (enExample) |
| AU (1) | AU2008209759B2 (enExample) |
| BR (1) | BRPI0806350A2 (enExample) |
| CA (1) | CA2675355C (enExample) |
| CL (1) | CL2008000249A1 (enExample) |
| DK (1) | DK2118292T3 (enExample) |
| IL (2) | IL199939A (enExample) |
| MX (1) | MX2009008118A (enExample) |
| PE (1) | PE20081723A1 (enExample) |
| PL (1) | PL2118292T3 (enExample) |
| RU (2) | RU2482189C2 (enExample) |
| TW (1) | TW200840869A (enExample) |
| WO (1) | WO2008092854A2 (enExample) |
| ZA (1) | ZA200904932B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415462B2 (en) | 2007-05-15 | 2013-04-09 | Transgene S.A. | Signaling peptides |
| US8337859B2 (en) * | 2007-05-15 | 2012-12-25 | Transgene S.A. | Vectors for multiple gene expression |
| WO2013055326A2 (en) * | 2011-10-12 | 2013-04-18 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| AU2014248535B2 (en) * | 2013-03-12 | 2017-03-30 | Inovio Pharmaceuticals, Inc. | Improved vaccines for human papilloma virus and methods for using the same |
| WO2015149051A1 (en) * | 2014-03-28 | 2015-10-01 | The Johns Hopkins University | Treatment regimen using cancer vaccines and local adjuvants and their use |
| AU2015341926B2 (en) * | 2014-11-04 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV16 vaccines |
| EP3283088A4 (en) * | 2015-04-17 | 2018-10-24 | Memorial Sloan-Kettering Cancer Center | Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors |
| SG11201810627UA (en) * | 2016-06-03 | 2018-12-28 | Etubics Corp | Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases |
| BE1024774B1 (fr) * | 2016-09-29 | 2018-07-02 | Glaxosmithkline Biologicals Sa | Compositions et procedes de traitement |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US11012555B2 (en) * | 2017-11-20 | 2021-05-18 | International Business Machines Corporation | Non-verbal sensitive data authentication |
| KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| US12391746B2 (en) | 2018-02-20 | 2025-08-19 | Emory University | HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth |
| US12377142B2 (en) | 2018-03-07 | 2025-08-05 | Transgene | Recombinant pseudocowpoxvirus |
| KR20210100115A (ko) | 2018-12-03 | 2021-08-13 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 올리고-벤즈아미드 유사체 및 암 치료에서의 이의 용도 |
| CN116200416B (zh) * | 2023-02-15 | 2024-03-12 | 北京康乐卫士生物技术股份有限公司 | 一种基于Tac启动子的质粒表达载体构建及其用途 |
| WO2025199501A1 (en) * | 2024-03-22 | 2025-09-25 | Gritstone Bio, Inc. | Human papillomavirus (hpv) vaccines |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| WO1994012629A1 (en) * | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| PL183781B1 (pl) * | 1994-05-16 | 2002-07-31 | Merck & Co Inc | Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| ATE550429T1 (de) | 1996-11-20 | 2012-04-15 | Crucell Holland Bv | Adenovirus-zusammensetzungen erhältlich durch ein verbessertes produktions- und reinigungsverfahren |
| DE69737364T2 (de) | 1996-12-13 | 2007-11-29 | Schering Corp. | Methoden zur virus-reinigung |
| EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| EP1012348B1 (en) | 1997-09-16 | 2002-06-12 | Innogenetics N.V. | Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization |
| FR2774699B1 (fr) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| US6582693B2 (en) * | 1998-11-30 | 2003-06-24 | Lemery, S.A. De C.V. | Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| HUP0104794A3 (en) | 1998-12-31 | 2006-03-28 | Centelion | Method for separating viral particles |
| DE60010654T2 (de) | 1999-02-04 | 2005-06-16 | Geron Corp., Menlo Park | Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs |
| AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| JP4799789B2 (ja) * | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 |
| CA2380537C (en) | 1999-11-15 | 2011-01-18 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| US20020029498A1 (en) * | 2000-07-03 | 2002-03-14 | Howard Harrison | Rapid cool iron and related iron improvements |
| DE60124918T2 (de) | 2000-07-21 | 2007-08-02 | Glaxo Group Ltd., Greenford | Kodon-optimierte papillomavirussequenzen |
| AU2002344190B2 (en) | 2001-05-30 | 2007-10-18 | Transgene S.A. | Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| EP1427443A4 (en) | 2001-08-23 | 2006-03-08 | Merck & Co Inc | VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR |
| EP1407033B1 (en) * | 2002-05-16 | 2006-01-11 | Bavarian Nordic A/S | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| EP1699479A1 (en) * | 2003-12-24 | 2006-09-13 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
| AU2005222776A1 (en) | 2003-12-31 | 2005-09-29 | Genimmune N.V. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
-
2008
- 2008-01-29 AU AU2008209759A patent/AU2008209759B2/en not_active Ceased
- 2008-01-29 JP JP2009547667A patent/JP5474567B2/ja not_active Expired - Fee Related
- 2008-01-29 BR BRPI0806350-8A patent/BRPI0806350A2/pt not_active Application Discontinuation
- 2008-01-29 AR ARP080100357A patent/AR065076A1/es not_active Application Discontinuation
- 2008-01-29 EP EP11175811A patent/EP2390340A3/en not_active Withdrawn
- 2008-01-29 EP EP08708349A patent/EP2118292B1/en not_active Not-in-force
- 2008-01-29 TW TW097103230A patent/TW200840869A/zh unknown
- 2008-01-29 DK DK08708349.9T patent/DK2118292T3/da active
- 2008-01-29 WO PCT/EP2008/051032 patent/WO2008092854A2/en not_active Ceased
- 2008-01-29 KR KR1020097016704A patent/KR101636575B1/ko not_active Expired - Fee Related
- 2008-01-29 PL PL08708349T patent/PL2118292T3/pl unknown
- 2008-01-29 CN CN200880003650A patent/CN101617052A/zh active Pending
- 2008-01-29 CA CA2675355A patent/CA2675355C/en not_active Expired - Fee Related
- 2008-01-29 CL CL200800249A patent/CL2008000249A1/es unknown
- 2008-01-29 US US12/449,197 patent/US8420103B2/en not_active Expired - Fee Related
- 2008-01-29 MX MX2009008118A patent/MX2009008118A/es active IP Right Grant
- 2008-01-29 AT AT08708349T patent/ATE518958T1/de not_active IP Right Cessation
- 2008-01-29 PE PE2008000212A patent/PE20081723A1/es not_active Application Discontinuation
- 2008-01-29 RU RU2009130791/10A patent/RU2482189C2/ru not_active IP Right Cessation
-
2009
- 2009-01-01 ZA ZA200904932A patent/ZA200904932B/xx unknown
- 2009-07-19 IL IL199939A patent/IL199939A/en active IP Right Grant
-
2011
- 2011-10-06 IL IL215599A patent/IL215599A/en not_active IP Right Cessation
-
2013
- 2013-01-17 RU RU2013102035/10A patent/RU2013102035A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL199939A0 (en) | 2010-04-15 |
| AR065076A1 (es) | 2009-05-13 |
| KR101636575B1 (ko) | 2016-07-05 |
| US8420103B2 (en) | 2013-04-16 |
| DK2118292T3 (da) | 2011-10-24 |
| CN101617052A (zh) | 2009-12-30 |
| EP2390340A2 (en) | 2011-11-30 |
| AU2008209759A1 (en) | 2008-08-07 |
| JP2010516287A (ja) | 2010-05-20 |
| KR20090129399A (ko) | 2009-12-16 |
| RU2009130791A (ru) | 2011-03-10 |
| AU2008209759B2 (en) | 2013-03-21 |
| RU2482189C2 (ru) | 2013-05-20 |
| ZA200904932B (en) | 2010-04-28 |
| IL199939A (en) | 2013-02-28 |
| CA2675355A1 (en) | 2008-08-07 |
| US20100143408A1 (en) | 2010-06-10 |
| JP5474567B2 (ja) | 2014-04-16 |
| WO2008092854A3 (en) | 2008-10-30 |
| EP2118292A2 (en) | 2009-11-18 |
| ATE518958T1 (de) | 2011-08-15 |
| IL215599A0 (en) | 2011-11-30 |
| PL2118292T3 (pl) | 2011-12-30 |
| RU2013102035A (ru) | 2014-07-27 |
| PE20081723A1 (es) | 2008-12-14 |
| EP2390340A3 (en) | 2012-02-22 |
| EP2118292B1 (en) | 2011-08-03 |
| MX2009008118A (es) | 2009-10-13 |
| CL2008000249A1 (es) | 2008-05-30 |
| CA2675355C (en) | 2015-04-28 |
| WO2008092854A2 (en) | 2008-08-07 |
| BRPI0806350A2 (pt) | 2011-09-06 |
| IL215599A (en) | 2014-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101636575B1 (ko) | 유두종바이러스 백신 | |
| US20100055069A1 (en) | Hpv-18-based papillomavirus vaccines | |
| KR101514473B1 (ko) | 다중 유전자 발현용 벡터 | |
| US20100061957A1 (en) | Hpv-16-based papillomavirus vaccines | |
| ES2370674T3 (es) | Polipéptido e2 de papilomavirus utilizado para la vacunación. | |
| AU2013201033A1 (en) | Papillomavirus E2 Polypeptide Used for Vaccination | |
| HK1135731B (en) | Vectors for multiple gene expression |